Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call
Optinose (NASDAQ:OPTN), a pharmaceutical company specializing in ENT and allergy treatments, has announced the cancellation of its Q4 and full-year 2024 earnings conference call originally scheduled for March 20, 2025. The cancellation follows the company's earlier announcement of a definitive agreement to be acquired by Paratek Pharmaceuticals.
The acquisition deal is subject to shareholder approval and other customary closing conditions. Despite the earnings call cancellation, Optinose confirms it will still report its financial results for both the three-month and twelve-month periods ended December 31, 2024, in a timely manner.
Optinose (NASDAQ:OPTN), un'azienda farmaceutica specializzata in trattamenti per Otorinolaringoiatria e allergie, ha annunciato la cancellazione della sua conferenza telefonica sui risultati finanziari del Q4 e dell'intero anno 2024, inizialmente programmata per il 20 marzo 2025. La cancellazione segue l'annuncio precedente dell'azienda riguardo a un accordo definitivo per essere acquisita da Paratek Pharmaceuticals.
Il contratto di acquisizione è soggetto all'approvazione degli azionisti e ad altre condizioni standard di chiusura. Nonostante la cancellazione della conferenza, Optinose conferma che riporterà comunque i suoi risultati finanziari sia per il periodo di tre mesi che per quello di dodici mesi terminati il 31 dicembre 2024, in modo tempestivo.
Optinose (NASDAQ:OPTN), una empresa farmacéutica especializada en tratamientos para otorrinolaringología y alergias, ha anunciado la cancelación de su conferencia telefónica sobre los resultados del cuarto trimestre y del año completo 2024, que estaba programada originalmente para el 20 de marzo de 2025. La cancelación sigue al anuncio previo de la empresa sobre un acuerdo definitivo para ser adquirida por Paratek Pharmaceuticals.
El acuerdo de adquisición está sujeto a la aprobación de los accionistas y a otras condiciones habituales de cierre. A pesar de la cancelación de la conferencia, Optinose confirma que aún informará sobre sus resultados financieros tanto para los períodos de tres meses como de doce meses que terminan el 31 de diciembre de 2024, de manera oportuna.
옵티노즈 (NASDAQ:OPTN), ENT 및 알레르기 치료를 전문으로 하는 제약 회사가 2025년 3월 20일로 예정된 2024년 4분기 및 연간 실적 발표 전화 회의를 취소한다고 발표했습니다. 이 취소는 파라텍 제약에 인수되는 최종 계약에 대한 회사의 이전 발표에 따른 것입니다.
인수 계약은 주주 승인 및 기타 관례적인 종료 조건에 따라야 합니다. 실적 발표 전화 회의가 취소되었음에도 불구하고, 옵티노즈는 2024년 12월 31일로 종료되는 3개월 및 12개월 기간에 대한 재무 결과를 적시에 보고할 것임을 확인합니다.
Optinose (NASDAQ:OPTN), une entreprise pharmaceutique spécialisée dans les traitements ORL et allergiques, a annoncé l'annulation de sa conférence téléphonique sur les résultats du quatrième trimestre et de l'année complète 2024, initialement prévue pour le 20 mars 2025. Cette annulation fait suite à l'annonce antérieure de l'entreprise concernant un accord définitif pour être acquis par Paratek Pharmaceuticals.
L'accord d'acquisition est soumis à l'approbation des actionnaires et à d'autres conditions de clôture habituelles. Malgré l'annulation de la conférence, Optinose confirme qu'elle publiera tout de même ses résultats financiers pour les périodes de trois mois et de douze mois se terminant le 31 décembre 2024, en temps voulu.
Optinose (NASDAQ:OPTN), ein Pharmaunternehmen, das sich auf HNO- und Allergiebehandlungen spezialisiert hat, hat die Absage seiner Telefonkonferenz zu den Ergebnissen des vierten Quartals und des gesamten Jahres 2024 bekannt gegeben, die ursprünglich für den 20. März 2025 angesetzt war. Die Absage folgt auf die frühere Ankündigung des Unternehmens über eine endgültige Vereinbarung zur Übernahme durch Paratek Pharmaceuticals.
Der Übernahmevertrag unterliegt der Genehmigung der Aktionäre und anderen üblichen Abschlussbedingungen. Trotz der Absage der Telefonkonferenz bestätigt Optinose, dass es dennoch seine finanziellen Ergebnisse für die drei- und zwölfmonatigen Perioden, die am 31. Dezember 2024 enden, zeitgerecht berichten wird.
- Definitive agreement reached for acquisition by Paratek Pharmaceuticals
- None.
YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cancellation of its earnings conference call for the quarter and full year ended December 31, 2024 that had originally been scheduled for March 20, 2025 at 8:00 a.m. Eastern Time.
The call is being cancelled due to the announcement earlier today that Optinose has entered into a definitive agreement to be acquired by Paratek Pharmaceuticals, subject to shareholder and other customary closing conditions.
The Company now expects to report results for the three- and twelve-month periods ended December 31, 2024, in a timely manner.
About Optinose
Optinose is a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on X and LinkedIn.
Optinose Investor Contact
Jonathan Neely
jonathan.neely@optinose.com
267.521.0531
FAQ
Why did Optinose (OPTN) cancel its Q4 2024 earnings call?
Will Optinose (OPTN) still release its Q4 and full-year 2024 financial results?
What are the conditions for Paratek's acquisition of Optinose (OPTN)?
When was Optinose's (OPTN) Q4 2024 earnings call originally scheduled?
